title: Do rheumatology cost-effectiveness analyses make sense?
authors.forename: F
authors.initials: F
authors.lastname: Wolfe
authors.forename: K
authors.initials: K
authors.lastname: Michaud
authors.forename: T
authors.initials: T
authors.lastname: Pincus
mesh_terms: D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics / Q000627:therapeutic use*; D018579:Patient Selection; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept